Lucas, Ignacio http://orcid.org/0000-0001-9426-5082
Solé-Morata, Neus http://orcid.org/0000-0003-0433-0843
Baenas, Isabel http://orcid.org/0000-0001-7415-0616
Rosinska, Magda http://orcid.org/0009-0009-9918-7592
Fernández-Aranda, Fernando http://orcid.org/0000-0002-2968-9898
Jiménez-Murcia, Susana http://orcid.org/0000-0002-3596-8033
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PDI2021-124887OB-I00, FJC2021-046494-I)
Plan Nacional sobre Drogas (2021I031)
Instituto de Salud Carlos III (PI20/00132, CM21/00172)
AGAUR-Generalitat de Catalunya (2021-SGR-00824)
Horizon 2020 (847879)
AGAUR (2020 FISDU 00579)
European Social Fund (CM21/00172)
Agencia Estatal de Investigación (FJC2021-046494-I)
European Union “NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (FJC2021-046494-I)
Universitat de Barcelona
Article History
Accepted: 29 May 2023
First Online: 4 July 2023
Compliance with Ethical Standards
:
: Dr. Fernández-Aranda and Dr. Jiménez-Murcia received consultancy honoraria from Novo Nordisk, and Dr. Fernández-Aranda received editorial honoraria as EIC from Wiley.
: Not applicable as no human or animal subjects were involved in this work.